Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine for Mild and Asymptomatic COVID-19
NCT04333628Phase 3
Key facts
- Status
- Terminated
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Countries
- 1
- Sponsor
- Emek Medical Center
- Modality
- Small Molecules
- Drugs
- chloroquine
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 3, randomised, open-label trial of chloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Emek Medical Center. Primary endpoints: change in virus duration (viral shedding) at 23 days and change in the number of patients going from asymptomatic to moderately disease at 1 month. Started Jun 2020; status: terminated.
02
Design
3 arms- Study design
- RandomizedOpen-label
Low dose chloroquine
Oral chloroquine 125mg daily for 7 days
Regular dose chloroquine
Oral chloroquine 500 mg twice daily for 7 days
Standard of care
Supportive care based on clinical state
03
Who it enrols
Adult patients diagnosed with COVID-19 in the past 48 hours who are asymptomatic or have mild symptoms. Patients with chronic lung disease, heart failure, arrhythmias, or those taking antibiotics/antiretrovirals are excluded.
04
Endpoints
Primary
change in virus duration (viral shedding)
change in the number of patients going from asymptomatic to moderately disease
Beyond the preview
Go deeper on NCT04333628.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333628.